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JoObjective: As glucagon-like peptide-1 receptor agonists
lower blood pressure (BP) in type 2 diabetes mellitus
(T2DM), we examined BP control in relation to targets set
by international bodies prior to randomization in the
Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) trial.
Methods: We analyzed baseline data from LEADER
(NCT01179048), an ongoing phase 3B, randomized,
double-blind, placebo-controlled cardiovascular outcomes
trial examining the cardiovascular safety of the glucagon-
like peptide-1 receptor agonist liraglutide in 9340 people
with T2DM from 32 countries [age (all mean SD)
647.2 years, BMI 32.5 6.3 kg/m2, duration of diabetes
12.78.0 years], all of whom were at high risk for
cardiovascular disease (CVD).
Results: A total of 81% (n¼7592) of participants had
prior CVD and 90% (n¼8408) had a prior history of
hypertension. Despite prescription of multiple
antihypertensive agents at baseline, only 51% were
treated to a target BP of less than 140/85mmHg and only
26% to the recommended baseline BP target of less than
130/80mmHg. In univariate analyses, those with prior CVD
were prescribed more agents (P< 0.001) and had lower BP
than those without (13718.8/7810.6mmHg versus
14017.7/809.9mmHg; P<0.001). In logistic
regression analyses, residency in North America (64%
treated to <140/85mmHg; 38% treated to <130/
80mmHg) was the strongest predictor of BP control.
Conclusion: These contemporary data confirm that BP
remains insufficiently controlled in a large proportion of
individuals with T2DM at high cardiovascular risk,
particularly outside North America. Longitudinal data from
the LEADER trial may provide further insights into BP
control in relation to cardiovascular outcomes in this
condition.
Keywords: blood pressure, cardiovascular disease,
glucagon-like peptide-1, regional differences, targets, type
2 diabetes mellitus
Abbreviations: CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; GLP-1, glucagon-likepyright © 2016 Wolters Kluwer Health, Inc. Unau
urnal of Hypertensionpeptide-1; LEADER, liraglutide effect and action in
diabetes, evaluation of cardiovascular outcome results;
SGLT-2, sodium–glucose linked transporter-2INTRODUCTIONA
s blood pressure (BP) control is an important
strategy for preventing cardiovascular and renal
complications in type 2 diabetes mellitus (T2DM)
[1,2], some treatment guidelines include disease-specific BP
targets [3,4]. However, these can be difficult to achieve,
even with multiple antihypertensive agents [5,6].thorized reproduction of this article is prohibited.
DOI:10.1097/HJH.0000000000000890
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Petrie et al.Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) is an ongoing
phase 3B global cardiovascular outcome trial examining the
cardiovascular safety and potential benefits of the gluca-
gon-like peptide-1 (GLP-1) analogue liraglutide in individ-
uals with T2DM at high risk of cardiovascular disease (CVD)
[7]. The primary objective is to assess the effect of treatment
with liraglutide comparedwith placebo (for at least 3.5 years
and up to 5 years) on the incidence of cardiovascular
events, as defined by the primary end point of cardiovas-
cular death, nonfatal myocardial infarction, or nonfatal
stroke in adult patients with T2DM.
The efficacy of BP-lowering agents is not greatly influ-
enced by BMI [8], but as BMI and BP are closely associated
[9], more agents are required to achieve BP targets in obese
individuals [8]. In T2DM, this therapeutic challenge is
compounded by weight gain in association with many
commonly used glucose-lowering agents (insulin, sulpho-
nylureas, and thiazolidinediones) [10,11]. In the UK
Prospective Diabetes Study, in which patients with T2DM
had a BMI 29.8 5.5 kg/m2 (mean SD) and a very con-
servative definition of ‘tight’ BP control (<150/85mmHg),
29% still required three or more antihypertensive agents [1].
Glucose-lowering agents that have been introduced
more recently either do not affect weight (e.g., dipeptidyl
peptidase-4 inhibitors) [10,11] or are associated with weight
reduction [e.g., GLP-1 receptor agonists [10,12]; sodium–
glucose linked transporter-2 (SGLT-2) inhibitors] [13]. When
added to another glucose-lowering therapy, liraglutide
treatment is associated with weight reduction of 1.2–
2.6 kg and SBP reduction of 2.3–6.7mmHg [14–18]. It
therefore has the potential to facilitate the achievement
of BP targets in overweight and obese patients already
being treated with multiple agents.
In the present study, we analyzed baseline data from the
LEADER trial to: describe BP control at the time of random-
ization; report rates of nonachievement of BP targets in
relation to contemporary and updated guidelines; and
determine the factors predicting nonachievement of targets
prior to randomization to liraglutide or placebo. During
the trial recruitment period (2010–2012), international
guidelines recommended a BP target of <130/80mmHg
in T2DM [3,4].
Prompted by initial analyses, we also examined BP
control categorized according to the geographical regions
represented in the trial.
RESEARCH DESIGNANDMETHODS
The LEADER study design and baseline characteristics have
been published previously [7]. Briefly, participants were
enrolled between September 2010 and April 2012 at
410 sites in 32 countries according to the following
inclusion criteria: patients with T2DM aged at least 50 years
with concomitant CVD, cerebrovascular disease, peripheral
vascular disease, chronic renal failure, or chronic heart
failure; or patients aged at least 60 years with one or more
of the following cardiovascular risk factors: microalbumi-
nuria or proteinuria, hypertension, and left ventricular
hypertrophy by ECG or imaging, left ventricular dysfunc-
tion by imaging, or ankle–brachial index less than 0.9. AllCopyright © 2016 Wolters Kluwer Health, Inc. Unau
2 www.jhypertension.compatients had baseline HbA1c at least 7.0% (53mmol/mol).
Exclusion criteria included type 1 diabetes mellitus, calci-
tonin at least 50 ng/l, use of GLP-1 receptor agonists,
dipeptidyl peptidase-4 inhibitors, or insulin preparations
other than human neutral protamine Hagedorn, long-acting
analogs, or premixed preparations within 3 months prior
to screening.
BP was measured at the screening visit following usual
practice for clinical research at each individual trial center,
with adherence to the following standards as a minimum.
Participants were asked to avoid caffeine, smoking, and
exercise at least 30min before measurement. Measure-
ments were taken with the participant in a sitting position,
with the legs uncrossed, and the back and arm supported.
Participants were sitting for at least 5min before the first
reading was taken. Two measurements at intervals of at
least 2min were performed. Participants and trial personnel
were advised not to talk during the measurements. The
manufacture and model of the semi-automated measure-
ment devices and the cuff sizes used were not recorded.
The mean of the two BP measurements was subsequently
calculated for use in analyses. In some individuals (<1%)
for whom measurements were not available from the
screening visit, those from the randomization visit were
used. Hypertension was defined as SBP at least 140mmHg,
a DBP at least 90mmHg, or an existing prescription of
antihypertensive medication.
A target BP of less than 130/80mmHg, as recommended
by the international authorities cited above [3,4,19], was
disseminated to all study sites as the LEADER Global Expert
Panel’s ‘Standard of Care’ guideline and was therefore the
principal target used in this analysis [7]. However, owing to
subsequent changes in BP target recommendations, we also
report achievement of targets according to the updated
European Societies of Hypertension and Cardiology 2013
target of 140/85mmHg [20] and the American Diabetes
Association 2015 target of less than 140/90mmHg [21].
Resistant hypertension was defined as prescription of four
or more antihypertensive agents (or for those with BP>140/
90mmHg, the prescription of three or more agents) [21].
Sites were grouped as being from: North America [USA
and Canada (n¼ 2821)]; Europe (Czech Republic, Poland,
Romania, Austria, Belgium, Denmark, Finland, France,
Germany, UK, Greece, Ireland, Italy, the Netherlands,
Spain, Sweden, Turkey, and Serbia; n¼ 3521); and other
[i.e. countries not easily grouped into geographical regions
(India, China, South Korea, Taiwan, South Africa, Australia,
Brazil, Mexico, Arab Emirates, Russia, and Israel; n¼ 2998)].
All study participants gave written informed consent.
The trial (NCT01179048) was approved by the relevant local
ethical committees and is being conducted in conformity
with the Declaration of Helsinki.
Statistical analysis
Distributions of continuous variables are described
by mean SD whereas categorical variables are listed as
numbers and percentages (%). Associations of prior CVD
status and global region with covariates and factors of
interest were screened using Fisher’s exact test and F-test,
respectively. Multiple logistic regression models were
developed to assess the association between dichotomizedthorized reproduction of this article is prohibited.
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Blood pressure control in type 2 diabetesuncontrolled hypertension end points and predefined
explanatory factors. Variable selection was decided on
before model fitting. Covariates were selected by consider-
ation of potential impact on hypertension ‘off-target’
measurements, based on review of the literature and
availability in the LEADER database. Main effects of all
covariates/factors were retained in the model, as the ample
sample size of the LEADER study allowed no need
for further variable selection. Statistical analyses were
performed using SAS 9.3 software (SAS Institute, Cary,
North Carolina, USA). Analyses were performed using data
available after the trial recruitment phase, which may be
subject to minor changes following closure of the database
at trial completion.
RESULTS
A total of 91% of LEADER participants, all of whom had
T2DM, were also hypertensive. In all 61% (n¼ 5665) of
LEADER participants were prescribed two or more, and
19% (n¼ 1811) three or more antihypertensive agents.
However, at the time of the baseline visit, only 51% were
treated to a target of less than 140/85mmHg and 26% to a
target of less than 130/80mmHg.
BP was lower in those who had prior CVD (81% of the
study population) in comparison with those who had not
(137 18.8/78 10.6mmHg vs. 140 17.7/80 9.9mmHg;
P<0.001). A higher proportion of these individuals
achieved recommended targets: 52 versus 44% for a target
BP of less than 140/85mmHg and 28 versus 21% for a target
BP of less than 130/80mmHg (both P< 0.001), presumably
reflecting the use of more antihypertensive agents (3 in
20.9 vs. 13.0%; P< 0.001). Those with prior CVD were
younger (63.9 7.6 vs. 65.8 5.2 years; P< 0.001) with a
higher proportion being men and White (Table 1, left hand
panel); estimated glomerular filtration rate was lower
(79.2 28.5 vs. 91.6 23.1ml/min per 1.73m2; P< 0.001)
although positive microalbuminuria status was less preva-
lent (13.9 vs. 48.6%; P< 0.001). HbA1c, duration of diabe-
tes, and BMI were similar between the groups with and
without prior CVD.
BP was higher in European participants (141 18.3/
79 10.2mmHg) than in those from North America
(133 18.1/75 10.5mmHg; P< 0.001) and other
countries (139 18.8/80 10.2mmHg) (P< 0.0001 for
both SBP and DBP), even though more were prescribed
three or more antihypertensive agents (23.0 vs. 19.0 vs.
16.0%, respectively; P< 0.001) (Table 1). BP target was
achieved in more participants in North America and other
countries than in Europe, that is, 63 vs. 48 vs. 42%,
respectively, for less than 140/85mmHg (P< 0.0001) and
38 vs. 23 vs. 20%, respectively, for less than 130/80mmHg
(P< 0.0001). Rates of achievement of BP control in indi-
vidual countries within the regional categories are shown in
Supplementary Table 1, http://links.lww.com/HJH/A595;
rates of SBP and DBP control individually are shown in
Supplementary Table 2, http://links.lww.com/HJH/A595.
BMI was higher in participants from North America than
in those from Europe and other countries (34.5 6.8 vs.
32.7 5.7 vs. 30.4 5.8 kg/m2; P< 0.0001); estimated glo-
merular filtration rate was lower (78 26.6 vs. 83 26.6 vs.opyright © 2016 Wolters Kluwer Health, Inc. Unau
Journal of Hypertension84 30.3ml/min per 1.73m2; P< 0.0001) and a higher
proportion were Black (17 vs. 0.5 vs. 9.6%; P< 0.0001).
However, resistant hypertension was present in a higher
proportion of Europeans compared with those from North
America and other countries (15.7 vs. 9.0 vs. 10.2%;
P< 0.0001). Documented duration of diabetes was shorter
in European than in North American and other participants
(11.6 7.4 vs. 13.5 8.6 vs. 13.3 8.0 years; P< 0.0001)
and HbA1c was lower (8.3 1.3 vs. 8.7 1.5 vs. 9.0 1.7%;
P< 0.0001). The prevalence of prior CVD did not differ
among participants recruited in North America and Europe
and similar proportions within each region were receiving
insulin treatment (Table 1).
In logistic regression analyses restricted to participants
prescribed at least one antihypertensive agent (and there-
fore operationally defined as having hypertension), the
strongest predictor of achievement of a BP target of either
less than 130/80mmHg (Fig. 1), less than 140/85mmHg
(Fig. 2), or less than 140/90mmHg (Fig. 3) was residence in
North America.
DISCUSSION
These baseline data from the ongoing LEADER trial provide
a cross-sectional description of BP control in a large cohort
of individuals across global regions with long-standing
T2DM and a high risk of CVD. At the time of randomization
to liraglutide or placebo, the prevalence of hypertension
(90%) was higher than in any other recent landmark trial of
glucose-lowering therapy in T2DM (as shown in Table 2),
though a proportion will have been misclassified as hyper-
tensive because of prescription of antihypertensive agents
for other indications. Nevertheless, despite this likely
degree of misclassification, we report that BP measure-
ments met the contemporary target set by most inter-
national bodies (<130/80mmHg) in only one-quarter
of participants.
LEADER was designed so that participants could be
recruited in either primary or secondary CVD prevention
categories: major baseline characteristics have already been
reported separately for these groups [7]. The present
analysis adds more detail to the previous report, giving
BP measurements in relation to treatment and targets.
In unadjusted analyses, BP was better controlled in
secondary prevention participants (who formed 81% of
the total) than in those in the primary prevention category;
this was in keeping with apparently more intensive
pharmacological management. These findings are consist-
ent with recently-reported baseline data from the secondary
prevention study entitled Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS study) in which a higher
proportion of participants who met the inclusion criteria
because of previous myocardial infarction were treated to a
target BP of less than 140/80mmHg than in those with
peripheral arterial disease but no prior cardiovascular event
[29]. In LEADER, hypertension was one of the comorbidities
specified for inclusion in the primary prevention category;
this was one of the criteria selected to ensure that those
randomized were at sufficient risk of CVD to provide
adequate statistical power for the safety and efficacy end
points. This may account, at least in part, for the apparentlythorized reproduction of this article is prohibited.
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ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER <30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.977 0.872; 1.093 0.6853
<0.0001
<0.0001
<0.0001
0.0745
0.0004
0.3259
0.3652
0.1600
0.2272
0.9131
<0.0001
<0.0001
<0.0022
<0.0001
0.8683
0.1780
0.6360
0.0535
0.8502
0.0956
0.0070
0.5612
0.1921
0.2708
0.2472
0.0060
0.0328
0.624; 0.833
0.711; 1.016
0.624; 0.873
0.561; 0.753
0.888; 1.451
1.013; 1.349
1.320; 1.597
1.854; 1.060
0.929; 1.620
0.928; 1.383
0.837; 1.171
1.785; 2.399
2.063; 2.677
0.737; 0.935
0.554; 0.782
0.491; 1.817
0.412; 1.170
0.472; 1.573
0.997; 1.317
0.831; 1.164
0.971; 1.451
1.058; 1.422
0.996; 1.002
0.944; 1.012
0.984; 1.059
0.982; 1.075
1.016; 1.102
0.722
0.850
0.738
0.650
1.131
1.168
1.451
1.951
1.000
1.221
1.131
1.991
1.000
2.068
2.350
1.000
0.830
0.658
1.000
0.946
0.699
0.865
1.000
1.146
0.984
1.186
1.226
0.999
0.977
1.021
1.027
1.058
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 1 Odds ratios for characteristics associated with blood pressure target of >130/80mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
Blood pressure control in type 2 diabeteshigher levels of baseline BP observed in this group. It
should be noted that the presence or absence of CVD
was not a significant determinant of BP in fully adjusted
analyses. Nevertheless, in both primary and secondary
prevention groups, there remained considerable scope
for treatment intensification, as only 21 and 13%, respect-
ively, were prescribed three or more antihypertensive
agents.
Participants recruited in European centers and other
countries had higher BP than those recruited in North
America (by mean SBP and DBP 8/4mmHg and 6/5mmHg,
respectively), although they were prescribed more antihy-
pertensive agents, had lower BMI (by 2 kg/m2 and 4 kg/m2,
respectively), and included fewer Black participants
(usually considered to be more likely to be treatmentopyright © 2016 Wolters Kluwer Health, Inc. Unau
Journal of Hypertensionresistant) [30]. Differences according to region of recruit-
ment did not appear to be accounted for by differences in
the demographic factors recorded.
Regional differences in control of BP have previously
been reported from population-based surveys. In general,
these have been consistent with the present observations,
namely that BP levels in Europe are on average higher than
in North America, particularly the USA [31,32]. These differ-
ences are not considered an artifact of method of measure-
ment or case selection in that higher prevalence of
hypertension at the population level is closely correlated
with higher rates of stroke mortality [31]. In surveys of
individuals without diabetes there can be higher rates of
case-finding in some countries (e.g. the US) than others,
biasing the mean BP of the treated population toward athorized reproduction of this article is prohibited.
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ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER >30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.957 0.867; 1.056
0.736; 0.934
0.803; 1.093
0.712; 0.955
0.608; 0.785
1.035; 1.582
1.055; 1.349
1.295; 1.520
0.850; 1.030
1.113; 1.779
0.931; 1.328
0.800; 1.060
1.649; 2.145
2.037; 2.582
0.827; 1.019
0.731; 1.003
0.536; 1.727
0.482; 1.215
0.486; 1.421
0.912; 1.165
0.912; 1.226
0.986; 1.392
0.987; 1.280
0.998; 1.003
0.960; 1.022
0.992; 1.058
1.015; 1.100
1.036;1.113
0.3828
0.0020
0.4083
0.0098
<0.0001
<0.0001
<0.0001
<0.0001
0.0001
0.0230
0.0050
0.1767
0.0043
0.2431
0.2485
0.1087
0.0544
0.8937
0.2564
0.4959
0.6275
0.4596
0.0724
0.0774
0.7003
0.5447
0.1383
0.0071
0.829
0.937
0.834
0.691
1.279
1.193
1.403
1.936
1.000
1.406
1.112
0.920
1.000
1.880
2.293
1.000
0.918
0.856
1.000
0.961
0.765
0.830
1.000
1.031
1.057
1.171
1.124
1.001
0.991
1.025
1.057
1.074
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 2 Odds ratios for characteristics associated with blood pressure target of >140/85mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
Petrie et al.lower level; this is unlikely to explain the present results, as
all participants were known cases of T2DM under routine
monitoring of BP. Neither can the differences be readily
explained by treatment intensity as the number of antihy-
pertensive agents prescribed per individual was similar in
Europe and the US [33].
Higher BP at the population level in Europe may not be
explained entirely by treatment effects, in that differences
can be observed even in young adults (few of whom have a
diagnosis of hypertension or are on BP-lowering treat-
ment): therefore, other environmental and/or genetic fac-
tors must also play a role [31]. Differences in BP in the
background populations from which participants were
drawn may have been reflected in the cohort randomized
in LEADER, but we acknowledge that the differences weCopyright © 2016 Wolters Kluwer Health, Inc. Unau
6 www.jhypertension.comreport may also, at least in part, have reflected differences in
sampling strategies among recruitment centers in Euro-
pean, North American, and other countries. Moreover,
we cannot exclude a higher prevalence of nonadherence
to therapy, more frequent prescription of less-effective
therapy, or more frequent use of subtherapeutic dosages
in European LEADER participants. There may also have
been a lower prevalence of treatment-refractory hyperten-
sion amongst North American participants.
After the completion of recruitment into LEADER,
BP targets were relaxed to less than 140/85mmHg by the
European Societies of Hypertension and Cardiology in 2013
[34]; they were then revised to less than 140/90mmHg by
the US Joint National Committee (JNC 8) [35] and the
American Diabetes Association [36]. Even beforethorized reproduction of this article is prohibited.
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ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER >30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.979 0.891; 1.077
0.746; 0.933
0.836; 1.120
0.746; 0.980
0.621; 0.799
1.051; 1.572
1.015; 1.285
1.333; 1.560
0.885; 1.066
1.130; 1.762
0.923; 1.303
0.798; 1.039
1.637; 2.112
2.104; 2.650
0.863; 1.055
0.777; 1.050
0.565; 1.778
0.490; 1.212
0.485; 1.388
0.907; 1.149
0.882; 1.173
1.023; 1.422
1.021; 1.311
0.998; 1.003
0.978; 1.038
0.994; 1.057
1.030; 1.113
1.095;1.174
0.6666
0.0015
0.6600
0.0243
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0144
0.0274
0.5377
0.0024
0.2944
0.1628
0.3610
0.1872
0.9987
0.2579
0.4959
0.7320
0.8129
0.0255
0.0225
0.4986
0.6149
0.1088
0.0005
0.834
0.968
0.855
0.704
1.286
1.142
1.442
0.971
1.000
1.411
1.097
0.910
1.000
1.859
2.360
1.000
0.954
0.904
1.000
1.000
0.770
0.819
1.000
1.021
1.017
1.206
1.157
1.001
1.008
1.025
1.071
1.134
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 3 Odds ratios for characteristics associated with blood pressure target of >140/90mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
Blood pressure control in type 2 diabetesrecruitment into LEADER began, discussions had been
initiated in Europe on potentially relaxing BP treatment
targets [37]. It is possible that clinical practice began to
change in European centers involved in LEADER prior to
the publication of revised targets and that early imple-
mentation of this change in practice contributed to the
higher mean BP levels we observed in European partici-
pants. This explanation has recently been invoked by the
Trial Evaluating Cardiovascular Outcomes with Sitagliptin
investigators to explain a similar mean difference in SBP
and DBP (8/4mmHg) at baseline between participants with
T2DM from North America versus Western Europe [29].
Even with revised targets, rates of BP control cannot be
considered satisfactory at baseline in LEADER, as these
were achieved only in 50–54% of trial participants.
Although these rates may at first sight seem low, they areopyright © 2016 Wolters Kluwer Health, Inc. Unau
Journal of Hypertensionin keeping with a contemporary pooled analysis of longi-
tudinal data from individuals with andwithout diabetes [38];
the literature suggests they are likely to be an improvement
on those that would have been observed a decade ago
[38–40]. The predictors of nonachievement of BP targets in
our analyses were broadly similar, independently of the
target figures used. The observation that BP control was
markedly better in the United States than in Europe in the
large samples of patients with T2DM and high cardiovas-
cular risk recruited into the LEADER trial prompts us to
reflect on the potential public health effects of the recent
global (European-led) relaxation of BP targets in terms of
hypertension-related cardiovascular outcomes, particularly
given that targets are infrequently achieved and BP low-
ering using currently available pharmacological agents is
well established to reduce rates of mortality and otherthorized reproduction of this article is prohibited.
www.jhypertension.com 7
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Blood pressure control in type 2 diabetescomplications [41]. The SPRINT trial has recently high-
lighted the benefits of BP-lowering in nondiabetic individ-
uals and hence rekindled enthusiasm for more intensive BP
targets in diabetes [42]. This has reopened discussion of the
results of the ACCORD trial [25] which provided a key
stimulus for relaxation of previous BP targets in individuals
with T2DM.
The strength of the present analysis is the large number
of patients studied at baseline in a clinical trial setting, with
data collection according to a standard protocol and use of
a central laboratory. Moreover, multiracial sampling of
individuals from a global population favors the general-
izability of our findings. However, as acknowledged above,
selection bias at study sites could have influenced
our results. Furthermore, measurement of BP was cross-
sectional rather than longitudinal and some details of the
methods of measurement within individual sites were
not available.
It is clear from the present analysis that BP targets are too
infrequently achieved in many individuals with T2DM.
Many mechanisms for resistance to therapy have been
identified and reviewed, including higher baseline BP
because of obesity, activation of the sympathetic nervous
system, changes in central hemodynamics [43], volume
overload, and renin–angiotensin system activation [41].
Glucose-lowering therapies that also possess BP-lowering
effects may therefore have an attractive profile from a CVD
prevention perspective, as demonstrated by a reduction in
cardiovascular death with the SGLT-2 inhibitor with empa-
gliflozin as recently reported in the EMPA-REG trial [44].
GLP-1 receptor agonists and SGLT-2 inhibitors reduce BP
in part via weight reduction, but also influence renal
sodium handling [12,45], whereas GLP-1 receptor agonists
may also have direct effects on the vasculature [12]. It is
reasonable to speculate that such agents may facilitate the
long-term achievement of BP targets in people with hyper-
tension and T2DM treated with multiple agents, although as
shown in the recent ELIXA trial, this will not necessarily
translate into cardiovascular benefit [46]. Moreover, it
should also be noted that in the LEADER trial, a ‘standard
of care’ approach was used, that is, any effect of GLP-1
therapy on BP between the groups as randomized over the
full duration of the trial may ultimately be offset by
additional therapy in the placebo arm.
In summary, the present data highlight that, even with
modern antihypertensive therapy, adequate control of BP is
not achieved in many high-risk individuals with T2DM,
particularly outside North America. Longitudinal data from
the LEADER trial may provide further insights into BP
control in relation to cardiovascular outcomes in this
condition.
ACKNOWLEDGEMENTS
The authors wish to thank David Dynnes Ørsted and Henrik
Wachmann from Novo Nordisk for support with statistical
analysis and coordination in the preparation of this study,
and Watermeadow Medical (supported by Novo Nordisk)
for editorial assistance. We are also greatly indebted to the
many people with type 2 diabetes worldwide who agreed
to participate in the LEADER trial.opyright © 2016 Wolters Kluwer Health, Inc. Unau
Journal of HypertensionPrior presentation: Abstracts based on this study were
presented as posters at the 51st European Association for
the Study of Diabetes Annual Meeting (EASD Stockholm,
14–18 September 2015; A-15-713) and the International
Diabetes Federation Meeting (IDF Vancouver, 30 Novem-
ber – 4 December 2015; 0113-PD).
Source of funding: Editorial assistance, provided by
Watermeadow Medical, was funded by Novo Nordisk.
Conflicts of interest
J.R.P. is a member of the LEADER Global Expert Panel for
which he has received honoraria and meeting expenses
from Novo Nordisk. He has also acted in an advisory
capacity under contracts between his employer and the
following companies: Alere, AstraZeneca, Boehringer-
Ingleheim, Eli-Lilly, GlaxoSmithKline, Janssen, Merck
Sharpe & Dohme, and Sanofi. He receives support-in-kind
for an investigator-led trial from Merck Group (Germany).
S.P.M. has received research grants and or consulting
fees from Amylin, Novo Nordisk, St. Jude Medical, Terumo,
The Medicines Company, and Volcano Corp. S.C.B. has
served in advisory panels for Astra-Zeneca, Boehringer
Ingelheim; Bristol-Meyers Squibb, Janssen, Eli Lilly, Merck
Sharpe & Dohme, Novo Nordisk and Sanofi, and as board
member for Glycosmedia. E.F. has served in advisory
panels for AstraZeneca/Bristol-Meyers Squibb, Bioton,
Boehringer Ingelheim, Johnson & Johnson, Novartis and
Novo Nordisk, and attended speaker’s bureau for AstraZe-
neca/Bristol-Meyers Squibb, Bioton, Boehringer Ingelheim,
Merck, Novo Nordisk and Servier. S.J. has served in advi-
sory panel/speaker’s bureau/as consultant, and received
research support from Abbott, Astra Zeneca, Bayer, Bristol-
Meyers Squibb, Boehringer Ingelheim, Daiichi-Sankyo,
Essex, GlaxoSmithKline, Janssen, Johnson & Johnson, Eli
Lilly, Merck, Merck Sharp & Dohme, Novo Nordisk, Novar-
tis, Pfizer, Roche, Sanofi-Aventis, Solvay, Takeda and Viat-
ris. L.M. has served in advisory panels for Janssen and Novo
Nordisk, received research support from Sanofi-Aventis,
attended speaker’s bureau for Abbott, Merck Sharp &
Dohme, Eli Lilly, Novo Nordisk, Sanofi-Aventis and Astra-
Zeneca, and has been involved in clinical trials sponsored
by Novo Nordisk, Sanofi-Aventis, GlaxoSmithKline and
Boehringer-Ingelheim. L.A.L. has served on advisory panels
for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Com-
pany, GlaxoSmithKline, Janssen Pharmaceuticals, Merck,
Novo Nordisk, Sanofi and Servier; received research sup-
port from AstraZeneca, Boehringer Ingelheim, Eli Lilly,
GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Pfizer,
Sanofi and Servier; attended speaker’s bureau for AstraZe-
neca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo
Nordisk and Sanofi. M.H. has served in advisory panels for
Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novo
Nordisk and Sanofi; attended speaker’s bureau for Eli Lilly
and Novo Nordisk; and received research support from
AstraZeneca/Bristol-Meyers Squibb and Eli Lilly. I.S. is an
investigator and/or a consultant without any direct financial
benefit under contracts between her employer and the
following companies: AstraZeneca, Boehringer Ingelheim,
Merck Sharp & Dohme, Novo Nordisk and Sanofi. M.O. has
served in advisory panels for Novo Nordisk, AstraZeneca,
Bristol-Meyers Squibb, Novartis, Eli Lilly, Servier, Sanofi,thorized reproduction of this article is prohibited.
www.jhypertension.com 9
CE: Swati; JH-D-15-00914; Total nos of Pages: 11;
JH-D-15-00914
Petrie et al.and Merck Sharp & Dohme, and attended speaker’s bureau
for Eli Lilly, Novo Nordisk, Sanofi, Servier, Novartis, Merck,
Merck Sharp & Dohme and Medtronic. M.S. has served in
advisory panels for Novo Nordisk, received research sup-
port from Novartis, and attended speaker’s bureau Astra-
Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp &
Dohme, Novartis, Novo Nordisk, and Servier. L.V.G. has
served on advisory panels for AstraZeneca, Boehringer
Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck
Sharp & Dohme, Novartis, Novo Nordisk and Sanofi U.S;
and attended speaker’s bureau for AstraZeneca, Boehringer
Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck
Sharp & Dohme, Novartis, Novo Nordisk and Sanofi U.S.
J.F.M. is an investigator and/or consultant receiving hono-
raria from Abbott, Bayer, Boehringer Ingelheim, Novo
Nordisk, Roche and Vifor. F.M.M.B. is a full-time employee
and stock holder of Novo Nordisk A/S. B.Z. has received
honoraria from AstraZeneca, Boehringer Ingelheim, Jans-
sen, Novo Nordisk, Merck, Sanofi, Eli Lilly and Takeda for
scientific advisory board meetings and presentations. His
institution has received research support from Novo Nor-
disk, Boehringer Ingelheim and Merck. N.R.P. has received
speaker’s fees from Novo Nordisk, Servier and Takeda. He
has also received fees to attend advisory board meetings
from Takeda and Novo Nordisk, and consultancy fees
regarding the conduct of randomized controlled trials from
Astra Zeneca and Novo Nordisk.
REFERENCES
1. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 1998; 317:703–713.
2. Patel A, ADVANCE Collaborative GroupMacMahon S, Chalmers J, Neal
B, Woodward M, et al. . Effects of a fixed combination of perindopril
and indapamide on macrovascular and microvascular outcomes in
patients with type 2 diabetes mellitus (the ADVANCE trial): a random-
ised controlled trial. Lancet 2007; 370:829–840.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano
G, et al. The Task Force for theManagement of Arterial Hypertension of
the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC). 2007 Guidelines for the management of
arterial hypertension. Eur Heart J 2007; 28:1462–1536.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL
Jr, et al. Seventh report of the joint national committee on prevention,
detection, evaluation, and treatment of high blood pressure. Hyper-
tension 2003; 42:1206–1252.
5. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure
control rates and outcomes. J Am Soc Hypertens 2014; 8:127–141.
6. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et
al. Prevention of cardiovascular events with an antihypertensive regi-
men of amlodipine adding perindopril as required versus atenolol
adding bendroflumethiazide as required, in the Anglo-Scandinavian
cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a
multicentre randomised controlled trial. Lancet 2005; 366:895–906.
7. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et
al. Design of the liraglutide effect and action in diabetes: evaluation of
cardiovascular outcome results (LEADER) trial. Am Heart J 2013;
166:823–830.
8. Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, et al.
Blood pressure control and cardiovascular outcomes in normal-weight,
overweight, and obese hypertensive patients treated with three differ-
ent antihypertensives in ALLHAT. J Hypertens 2014; 32:1503–1513.
9. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and
blood pressure. Findings in hypertension screening of 1 million Amer-
icans. JAMA 1978; 240:1607–1610.
10. Ismail-Beigi F. Clinical practice. Glycemic management of type 2
diabetes mellitus. N Engl J Med 2012; 366:1319–1327.Copyright © 2016 Wolters Kluwer Health, Inc. Unau
10 www.jhypertension.com11. Petrie JR, Adler A, Vella S. What to add in with metformin in type 2
diabetes? QJM 2011; 104:185–192.
12. Petrie JR. The cardiovascular safety of incretin-based therapies: a
review of the evidence. Cardiovasc Diabetol 2013; 12:130–142.
13. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor
inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open ; 2:; pii
e001007.
14. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et
al. Liraglutide, a once-daily human GLP-1 analogue, added to a
sulphonylurea over 26 weeks produces greater improvements in
glycaemic and weight control compared with adding rosiglitazone
or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med
2009; 26:268–278.
15. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al.
Efficacy and safety comparison of liraglutide, glimepiride, and placebo,
all in combination with metformin, in type 2 diabetes the LEAD
(liraglutide effect and action in diabetes)-2 study. Diabetes Care
2009; 32:84–90.
16. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi
H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy
for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III,
double-blind, parallel-treatment trial. Lancet 2009; 373:473–481.
17. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al.
Efficacy and safety of the human glucagon-like peptide-1 analog
liraglutide in combination with metformin and thiazolidinedione in
patients with type 2 diabetes (LEAD-4 MetþTZD). Diabetes Care 2009;
32:1224–1230.
18. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al.
Liraglutide vs insulin glargine and placebo in combination with met-
formin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5
metþSU): a randomised controlled trial. Diabetologia 2009; 52:2046–
2055.
19. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M.
Reappraisal of European guidelines on hypertension management: a
European Society of Hypertension Task Force document. J Hypertens
2009; 27:2121–2158.
20. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, BohmM, et al.
2013 ESH/ESC Guidelines for the management of arterial hypertension
The Task Force for the management of arterial hypertension of the
European Society of Hypertension (ESH) and of the European Society
of Cardiology (ESC). J Hypertens 2013; 31:1281–1357.
21. AmericanDiabetes Association. Standards of medical care in diabetes –
2015. Diabetes Care 2015; 38 (Suppl. 1):S1–S93.
22. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL,
et al. Alogliptin after acute coronary syndrome in patients with type 2
diabetes. N Engl J Med 2013; 369:1327–1335.
23. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et
al. Saxagliptin and cardiovascular outcomes in patients with type 2
diabetes mellitus. N Engl J Med 2013; 369:1317–1326.
24. Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, et al.
Baseline characteristics of the patient population in the Saxagliptin
Assessment of Vascular Outcomes Recorded in patients with diabetes
mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013; 29:417–
426.
25. ACCORD study group. Effects of intensive blood-pressure control in
type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.
26. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M,
et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent
combination therapy for type 2 diabetes (RECORD): a multicentre,
randomised, open-label trial. Lancet 2009; 373:2125–2135.
27. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti
M, Moules IK, et al., PROactive investigators. Secondary prevention of
macrovascular events in patients with type 2 diabetes in the PROactive
Study (prospective pioglitazone clinical trial in macrovascular events):
a randomised controlled trial. Lancet 2005; 366:1279–1289.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with con-
ventional treatment and risk of complications in patients with type 2
diabetes (UKPDS 33). Lancet 1998; 352:837–853.
29. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR,
TECOS Executive Committee. Regional, age and sex differences in
baseline characteristics of patients enrolled in the trial evaluating
cardiovascular outcomes with sitagliptin (TECOS). Diabetes Obes
Metab 2015; 17:395–402.thorized reproduction of this article is prohibited.
Volume 34  Number 1  Month 2016
CCE: Swati; JH-D-15-00914; Total nos of Pages: 11;
JH-D-15-00914
Blood pressure control in type 2 diabetes30. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend
RR, et al. Detection, evaluation, and treatment of severe and resistant
hypertension: proceedings from an American Society of Hypertension
Interactive forum held in Bethesda, MD, U.S.A. J Am Soc Hypertens
2014; 8:743–757.
31. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres
M, et al. Hypertension prevalence and blood pressure levels in 6
European countries, Canada, and the United States. JAMA 2003;
289:2363–2369.
32. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et
al., Global Burden of Metabolic Risk Factors of Chronic Diseases
Collaborating Group (Blood Pressure). National, regional, and global
trends in systolic blood pressure since 1980: systematic analysis of
health examination surveys and epidemiological studies with 786
country-years and 54 million participants. Lancet 2011; 377:568–577.
33. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres
MR, et al. Hypertension treatment and control in five European
countries, Canada, and the United States.Hypertension 2004; 43:10–17.
34. ESH/ESC Task Force for the Management of Arterial Hypertension.
2013 Practice guidelines for themanagement of arterial hypertension of
the European Society of Hypertension (ESH) and the European Society
of Cardiology (ESC): ESH/ESC Task Force for the Management of
Arterial Hypertension. J Hypertens 2013; 31:1925–1938.
35. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C,
Handler J, et al. 2014 evidence-based guideline for the management of
high blood pressure in adults: report from the panel members
appointed to the Eighth Joint National Committee (JNC 8). JAMA
2014; 311:507–520.
36. American Diabetes Association. Standards of medical care in diabetes
2014. Diabetes Care 2014; 37 (Suppl 1):S14–S80.
37. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caul-
field MJ, et al. Reappraisal of European guidelines on hypertensionopyright © 2016 Wolters Kluwer Health, Inc. Unau
Journal of Hypertensionmanagement: a European Society of Hypertension Task Force docu-
ment. Blood Press 2009; 18:308–347.
38. Ru¨ckert IM, Baumert J, Schunk M, Holle R, Schipf S, Vo¨lzke H, et al.
Blood pressure control has improved in people with and without type
2 diabetes but remains suboptimal: a longitudinal study based on the
German DIAB-CORE consortium. PLoS One 2015; 10:e0133493.
39. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and
cardiovascular prognosis in patients with diabetes: 30 years of prog-
ress. J Hypertens Suppl 2008; 26:S7–13.
40. Borzecki AM, Berlowitz DR. Management of hypertension and diabe-
tes: treatment goals, drug choices, current practice, and strategies for
improving care. Curr Hypertens Rep 2005; 7:439–449.
41. Eguchi K, Pickering TG, Kario K. Why is blood pressure so hard to
control in patients with type 2 diabetes? J Cardiometab Syndr 2007;
2:114–118.
42. SPRINT Research GroupWright JT Jr, Williamson JD, Whelton PK,
Snyder JK, Sink KM, et al. . A randomized trial of intensive versus
standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.
43. Agnoletti D, Lieber A, Zhang Y, Protogerou AD, Borghi C, Blacher J,
Safar ME. Central hemodynamic modifications in diabetes mellitus.
Atherosclerosis 2013; 230:315–321.
44. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 dia-
betes. N Engl J Med 2015; 373:2117–2128.
45. Wilding JP. The role of the kidneys in glucose homeostasis in type 2
diabetes: clinical implications and therapeutic significance through
sodium glucose co-transporter 2 inhibitors. Metabolism 2014;
63:1228–1237.
46. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et
al. Lixisenatide in patients with type 2 diabetes and acute coronary
syndrome. N Engl J Med 2015; 373:2247–2257.Reviewers’ Summary Evaluations
Reviewer 1
The study illustrates baseline characteristics of type 2 dia-
betic patients included in the LEADER 4 trial, thus reporting
that the overall blood pressure control rate (<140/90
mmHg) is relatively poorly achieved, particularly when
considering the more intensive blood pressure targets
(<130/80 mmHg). This is of potential clinical relevance,
since the issue concerning the most appropriate blood
pressure targets to be achieved in high-risk hypertensive
patients with diabetes is still actively debated. For these
reasons, a closer analysis of baseline cardiovascular riskstratification might be of help for properly interpreting the
future outcomes of this trial.
Reviewer 2
This study presents data from the LEADER trial, confirming
the relatively poor levels of blood pressure control
achieved in type 2 diabetes patients at high cardiovascular
risk, especially according to more strict BP targets and in
countries other than North America. Despite the fact that
comparability is limited by the nature of a multicenter trial,
with different sampling schemes, this study provides an
informative contemporary, inter-region perspective on BP
control among diabetes patients.thorized reproduction of this article is prohibited.
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